The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Friday, February 26, 2021
Akero has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin for NASH.
read more
Janssen Research & Development
The FDA issued an EUA for the third vaccine for the prevention of COVID-19.
read more
Regeneron announced changes to the Phase 3 trial assessing investigational REGEN-COV in outpatients with COVID-19, following recommendations from the ...
read more
The FDA issued an EUA for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19.
read more
Wednesday, March 03, 2021
GW announced the CHMP has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX as an adjunctive treatment of ...
read more
Wednesday, March 03, 2021
Agios has submitted a sNDA to the FDA for TIBSOVO as a potential treatment for patients with previously treated isocitrate dehydrogenase 1 mutated ...
read more
Chimerix, worldwide licensee of Cantex's DSTAT investigational product, has reported promising results of the first cohort of patients hospitalized ...
read more
Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX in patients with AMD...
read more
Neurocrine Biosciences announced investigational drug luvadaxistat did not meet its primary endpoint in the Phase II INTERACT study in adults with ...
read more
NeuroSense has announced the successful completion of its first Phase IIa study.
read more
eXIthera announced the FDA has accepted its IND application to initiate a trial for EP-7041, a small-molecule inhibitor of coagulation Factor XIa.
read more
Blueprint announced the EMA has validated the company's Type II variation marketing authorization application for AYVAKYT for the treatment of ...
read more
GeoVax Labs announced the filing of two additional patent applications important to the Company’s key focus on vaccines against SARS-CoV-2 and cancer ...
read more
Apellis announced the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions...
read more
BioEclipse Therapeutics™ announced the administration of the first dose of CRX100 to a volunteer in the ongoing Phase 1 clinical trial in patients ...
read more